Alginate Sulfate-Nanoparticles Loaded with Hepatocyte Growth Factor and Insulin-Like Growth Factor-1 Improve left ventricular repair in a Porcine Model of Myocardial Ischemia Reperfusion Injury.

Nanomedicine offers great potential for the treatment of cardiovascular disease and particulate systems have the capacity to markedly improve bioavailability of therapeutics. The delivery of pro-angiogenic hepatocyte growth factor (HGF) and pro-survival and pro-myogenic insulin-like growth factor (IGF-1) encapsulated in Alginate-Sulfate nanoparticles (AlgS-NP) might improve left ventricular (LV) functional recovery after myocardial infarction (MI). In a porcine ischemia-reperfusion model, MI is induced by 75 min balloon occlusion of the mid-left anterior descending coronary artery followed by reperfusion. After 1 week, pigs (n=12) with marked LV-dysfunction (LV ejection fraction, LVEF<45%) are randomized to fusion imaging-guided intramyocardial injections of 8mg AlgS-NP prepared with 200µg HGF and IGF-1 (HGF/IGF1-NP) or PBS (Control). Intramyocardial injection is safe and pharmacokinetic studies of Cy5-labeled NP confirm superior cardiac retention compared to intracoronary infusion. Seven weeks after IM-injection of HGF/IGF1-NP, infarct size, measured using magnetic resonance imaging, is significantly smaller than in controls and is associated with increased coronary flow reserve. Importantly, HGF/IGF1-NP-treated pigs show significantly increased LVEF accompanied by improved myocardial remodeling. These findings demonstrate the feasibility and efficacy of using AlgS-NP as a delivery system for growth factors and offer the prospect of innovative treatment for refractory ischemic cardiomyopathy.

[1]  Jing-jing Xu,et al.  Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction , 2021, International journal of nanomedicine.

[2]  K. Cheng,et al.  All Roads Lead to Rome (the Heart): Cell Retention and Outcomes From Various Delivery Routes of Cell Therapy Products to the Heart , 2021, Journal of the American Heart Association.

[3]  H. Turnquist,et al.  Biologics and Their Delivery Systems: Trends in Myocardial Infarction. , 2021, Advanced drug delivery reviews.

[4]  James J. H. Chong,et al.  Growth factor therapy for cardiac repair: an overview of recent advances and future directions , 2020, Biophysical Reviews.

[5]  Wuqiang Zhu,et al.  Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease , 2020, Frontiers in Bioengineering and Biotechnology.

[6]  A. Bayés‐Genís,et al.  Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model , 2020, Scientific Reports.

[7]  D. Catalucci,et al.  Cardiovascular nanomedicine: the route ahead. , 2019, Nanomedicine.

[8]  R. Misra,et al.  The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine. , 2019, Cytokine & growth factor reviews.

[9]  D. Kraitchman,et al.  Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery , 2018, Front. Bioeng. Biotechnol..

[10]  E. Garbayo,et al.  Heart tissue repair and cardioprotection using drug delivery systems. , 2018, Maturitas.

[11]  V. Fast,et al.  Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell–Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine , 2017, Circulation.

[12]  Evgenios Neofytou,et al.  Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. , 2016, JAMA cardiology.

[13]  Smadar Cohen,et al.  Spontaneous Coassembly of Biologically Active Nanoparticles via Affinity Binding of Heparin-Binding Proteins to Alginate-Sulfate. , 2016, Nano letters.

[14]  C. Hodgkinson,et al.  Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. , 2016, Circulation research.

[15]  S. Gatti,et al.  Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. , 2015, Clinical science.

[16]  Ying Ge,et al.  Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. , 2014, Cell stem cell.

[17]  H. Heidbuchel,et al.  Three-dimensional rotational angiography fused with multimodal imaging modalities for targeted endomyocardial injections in the ischaemic heart. , 2014, European heart journal cardiovascular Imaging.

[18]  A. From,et al.  Intra-Myocardial Injection of Both Growth Factors and Heart Derived Sca-1+/CD31− Cells Attenuates Post-MI LV Remodeling More Than Does Cell Transplantation Alone: Neither Intervention Enhances Functionally Significant Cardiomyocyte Regeneration , 2014, PloS one.

[19]  Pieter A. Doevendans,et al.  Sustained Delivery of Insulin-Like Growth Factor-1/Hepatocyte Growth Factor Stimulates Endogenous Cardiac Repair in the Chronic Infarcted Pig Heart , 2014, Journal of Cardiovascular Translational Research.

[20]  H. Arnesen,et al.  Cell treatment after acute myocardial infarction prevents early decline in circulating IGF-1 , 2010, Scandinavian cardiovascular journal : SCJ.

[21]  Smadar Cohen,et al.  The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. , 2010, Biomaterials.

[22]  F. Van de Werf,et al.  Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. , 2010, Journal of the American College of Cardiology.

[23]  Smadar Cohen,et al.  The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. , 2009, Biomaterials.

[24]  Smadar Cohen,et al.  The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. , 2008, Biomaterials.

[25]  A. Yeung,et al.  Novel Index for Invasively Assessing the Coronary Microcirculation , 2003, Circulation.

[26]  G. Heyndrickx,et al.  Coronary Thermodilution to Assess Flow Reserve: Experimental Validation , 2001, Circulation.

[27]  Panos Vardas,et al.  European Society of Cardiology: Cardiovascular Disease Statistics 2017. , 2018, European heart journal.

[28]  P. Nigro,et al.  Cell therapy for heart disease after 15 years: Unmet expectations , 2018, Pharmacological research.

[29]  J. Leor,et al.  The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. , 2011, Biomaterials.

[30]  Frederik Maes,et al.  Non-invasive characterization of the area-at-risk using magnetic resonance imaging in chronic ischaemia. , 2011, Cardiovascular research.